Axonics is a medical technology company that develops and commercializes products for adults with bladder and bowel dysfunction, including: implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence and urinary urgency frequency, together referred to as overactive bladder, as well as fecal incontinence, and non-obstructive urinary retention; and a urethral bulking agent to treat female stress urinary incontinence. Co.'s proprietary rechargeable SNM system is designed to provide magnetic resonance imaging access, programmers, and long recharging interval among rechargeable SNM systems. The AXNX average annual return since 2018 is shown above.
The Average Annual Return on the AXNX average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AXNX average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AXNX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|